PRAMEELA BADDIGAM: Open Payments
NPI 1952302861 · REDLANDS, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,046 in 41 payments from 13 companies in 2025. Trend: 2023 $1,393 · 2024 $966 · 2025 $1,046
Food & beverage: $1,046
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 8 | $256 |
| Axsome Therapeutics, Inc. | 3 | $156 |
| Neurocrine BioSciences, Inc. | 7 | $144 |
| Teva Pharmaceuticals USA, Inc. | 4 | $94 |
| Collegium Pharmaceutical, Inc. | 3 | $72 |
| Alkermes, Inc. | 3 | $71 |
| Otsuka America Pharmaceutical, Inc. | 3 | $68 |
| Vanda Pharmaceuticals Inc. | 2 | $58 |
| Lundbeck LLC | 3 | $52 |
| Orexo US, Inc. | 2 | $37 |
Products named: COBENFY, Auvelity, INGREZZA, AUSTEDO XR, Jornay PM, ABILIFY ASIMTUFII, FANAPT, REXULTI.
Industry payments across CA — which companies pay providers there.
